DEA Labels Lab Buzz as Cannabimimetic Schedule I Threats
Published Date: 1/20/2026
Rule
Summary
Starting February 19, 2026, the DEA is officially defining “cannabimimetic agents” and adding 18 new substances to this group, all still Schedule I drugs. They’re also simplifying things by giving most of these substances one single drug code, making tracking easier. This update affects manufacturers, law enforcement, and anyone handling these substances, but it won’t change their legal status or cause new fees.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Eighteen substances formally listed
Starting February 19, 2026, DEA adds 18 additional named substances to the definition of “cannabimimetic agents.” All 18 substances remain Schedule I controlled substances, so their legal schedule status does not change.
Single DEA drug code for most agents
DEA consolidates most existing administration controlled substances codes for cannabimimetic agents into a single drug code number 7000 when the rule takes effect on February 19, 2026, to simplify tracking and reporting.
Two substances moved but keep existing codes
JWH-018 and AM2201 are moved to 21 CFR 1308.11(d) but retain their existing drug codes (7118 and 7201) to facilitate quota and international reporting; upon that move, positional isomers of these two substances will be defined as Schedule I controlled substances.
No new fees or reporting obligations
DEA states this final rule does not change the Schedule I status of listed substances, does not impose new regulatory controls, recordkeeping, reporting requirements, or information-collection burdens, and will not create new fees for handlers.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-14286, Importer of Controlled Substances Application: Catalent Greenville, Inc.
Catalent Greenville, Inc. wants to become an official importer of some powerful controlled substances, including LSD and related drugs. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 17, 2026. This move could impact how these substances enter the U.S., but no costs or fees are mentioned yet.
2026-14136, Barlow St-Clair Lynch, M.D.; Decision and Order
Dr. Barlow St-Clair Lynch from Maine lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately, impacting his medical practice and any related income.
2026-14135, David Enright, M.D.; Decision and Order
Dr. David Enright from Maine lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-14137, Shane Lydon, M.D.; Decision and Order
Dr. Shane Lydon's license to handle controlled substances in Maine has been revoked because he lost his state authority and didn’t ask for a hearing. This means he can no longer prescribe or manage these drugs, effective immediately. Anyone relying on his registration should update their records and note this change to avoid legal trouble.
Previous / Next Documents
Previous: 2026-00904, Commercial Non-Power Production or Utilization Facilities
The Nuclear Regulatory Commission just clarified that commercial non-power nuclear facilities must follow certain safety update rules, while non-commercial ones don’t. This change kicks in right away and affects businesses running these facilities, who now have 30 days to share their thoughts. No new fees are mentioned, but staying in the loop is key to avoid surprises!
Next: 2026-00909, Allocation of Assets in Single-Employer Plans; Interest Assumptions for Valuing Benefits
Starting January 31, 2026, new rules change how single-employer pension plans calculate the value of benefits when plans end. These updated interest assumptions affect plan sponsors and the Pension Benefit Guaranty Corporation, helping make sure money values match real market prices. If you’re involved with these plans, expect more accurate numbers for payouts and possible impacts on withdrawal costs.